• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Wellcome Trust, KU Leuven, Janssen collaborate

Wellcome Trust, KU Leuven, Janssen collaborate

September 4, 2013
CenterWatch Staff

Wellcome Trust, Janssen and KU Leuven are collaborating for dengue antiviral drugs. The collaboration will build on an existing three-year drug discovery program at the Rega Institute and the Center for Drug Design and Discovery (CD3) at KU Leuven, supported by a Wellcome Trust Seeding Drug Discovery Award.

This effort resulted in the identification of a series of chemical compounds that are highly potent inhibitors of dengue virus replication. The compounds have a novel mechanism of action, are active against all four serotypes of the dengue virus including clinical isolates, have a high barrier to resistance and have generated proof-of-concept data in animal models.

The alliance will enable the team to progress the compounds toward a first-in-class drug candidate for the prevention and treatment of infections with dengue virus. Janssen will have the option to further develop the candidate drug toward regulatory approval, with the goal of bringing the drug to patients globally.

Janssen will make an upfront payment and milestone payments based on achieving development, regulatory and sales goals. KU Leuven is also eligible to receive royalty payments on net sales of future products discovered or developed under the agreement.

Recent estimates indicate there may be as many as 390 million dengue infections across the globe each year, of which 96 million develop symptoms associated with the infection; however, currently there are no approved vaccines to prevent infection or approved drugs that stop the replication and spread of the dengue virus. Current approaches to treating the condition focus on alleviating symptoms.

Ted Bianco, director of technology transfer and acting director of the Wellcome Trust, said, "We urgently need dengue medications that combat the virus rather than the symptoms of infection. This agreement highlights the importance of seed funds, like the awards provided under Seeding Drug Discovery, to reduce the risk of drug discovery programs so that they become attractive to partners with the ability to bring a product to market.”

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing